J.P. Morgan Healthcare Conference (Idenix) - Jan 24, 2012 - IDX-184 / Idenix; Anticipated removal of partial clinical hold in 2012 for HCV; Anticipated combining with DAAs for regimen and initiate P2b trials in 2012 for HCV; Anticipated collaboration in 2012 for HCV
Anticipated clinical plan • Anticipated corporate collaboration • Anticipated P2b trial initiation • Hepatitis C Virus
|
|
IDX-184
-- -- --
Nucleotide HCV Polymerase Inhibitor for 2012
Potential removal of the partial clinical hold in 2012 for HCV
Combine with one or more DAAs for combination regimen and initiate broad Phase IIb trials in 2012 for HCV
Establish non-exclusive/exclusive collaboration in 2012 for HCV
-- -- --
|